The combination of the ICI with cytotoxic regimens proved to be more effective than either regimen used separately for the combination of capecitabine/oxaliplatin with anti-PD-1 Mab in the MC38 colorectal cancer model (Figure 1D) as well as with the combination of MVAC with anti-PD-L1 Mab in the MB49 bladder cancer (Figure 1C) while anti-PD-1 in combination with the MVAC regimen did not show any improved activity in the MB49 model (Figure S2B). This evidence concerns the gene PDCD1 and urinary bladder carcinoma.